Immunocore Holdings plc — Investor Relations & Filings

Immunocore Holdings plc is a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies. Its proprietary ImmTAX (Immune mobilizing monoclonal TCRs against X disease) platform is designed to harness the body's immune system. The technology engineers TCRs to recognize and target diseased cells, making them visible for destruction by the immune system, or to suppress the immune system in autoimmune conditions. The company's diverse clinical pipeline targets a broad range of indications, including solid tumors, infectious diseases such as HIV and hepatitis B, and autoimmune disorders. Immunocore developed and commercialized the world's first approved TCR therapy.